Therapy and risk-stratification in hypertrophic cardiomyopathy - A current survey;Therapie und risikostratifizierung der hypertrophen kardiomyopathie ein aktueller überblick

Zeitschrift fur Kardiologie

Volumn 92, Issue 4, 2003, Pages 283-293

  Reith, Sebastian ^a   Klues, Heinrich G ^a  

^a Klinikum Krefeld   (Germany)

Author keywords

Genetics; Hypertrophic cardiomyopathy; Risk stratification; TASH; Therapy

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DISOPYRAMIDE; VERAPAMIL;

COMORBIDITY; DEFIBRILLATOR; FAMILY HISTORY; FOLLOW UP; GENE MUTATION; GENOTYPE; HEART ATRIUM PACING; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE PACING; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MUSCLE RESECTION; NON INVASIVE MEASUREMENT; PHENOTYPE; PRIMARY PREVENTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STANDARD; SUDDEN DEATH; SURGICAL RISK; SYMPTOM; SYNCOPE;

CARDIOMYOPATHY, HYPERTROPHIC; CARDIOVASCULAR AGENTS; COMBINED MODALITY THERAPY; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART SEPTUM; HUMANS; PACEMAKER, ARTIFICIAL; SURGICAL PROCEDURES, MINIMALLY INVASIVE; SURVIVAL RATE; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 0037397550     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-003-0898-3     Document Type: Review

References (75)

1. Adelman AG, Shah PM, Gramiak R, Wrigle E (1970) Long term propanolol therapy in muscular subaortic stenosis. Br Heart J 32:804-811
2. Anan R, Greve G, Thierfelder L, Watkins H, McKenna WJ, Solomon S, Vecchio C, Shono H, Nakao S, Tanaka H et al (1994) Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 93:280-285
3. Beahrs MM, Tajik AJ, Seward JB, Giuliani ER, McGoon DC (1983) Hypertrophic obstructive cardiomyopathy, ten to 21-years follow-up after partial septal myectomy. Am J Cardiol 51:1160-1166
4. Bigelow W, Trimble AS, Anger P, Marquis Y, Wigle ED (1966) The ventriculomyotomy operation for muscular subaortic stenosis, a reappraisal. J Thorac Cardiovasc Surg 52(4)
5. Boekstegers P, Steinbigler P, Molnar A, Schwalbmair M, Becker A, Knez A, Habert R, Steinbeck G (2001) Pressure-guided non-surgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:846-853
6. Braunwald E (1997) Induced septal infarction. A new therapeutic strategy for hypertrophic obstructive cardiomyopathy. Circulation 95:1981-1982
7. Braunwald E, Morrow AG, Cornell WP, Aygeu MM, Hilbish TF (1960) Idiopathic hypertrophic subaortic stenosis: Clinical hemodynamic and angiographic manifestations. Am J Med 29:924-945
8. Brock R (1957) Functional obstruction of the left ventricle. Guys Hosp Rep 106:221
9. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolora A Maron BJ (1998) Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy. Heart 79:331-336
10. Cleland WP (1963) The surgical management of obstructive cardiomyopathy. J Cardiovasc Surg 4:489-491
11. Cooley DA, Leachman RD, Hallmann GL (1971) Idiopathic hypertrophic subaortic stenosis: surgical treatment including mitral valve replacement: Arch Surg 103:606-612
12. Elliott PM, Gimeno Blanes BJ, Mahon NG, Poloniecki DJ, McKenna WJ (2001) Relation between severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 357:420-424
13. Elliott PM, Poloniecki DJ, Dieckie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ (2000) Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36:2212-2218
14. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ (1999) Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 33:1596-1601
15. Faber L, Meissner A, Ziemssen P, Seggewiss H (2000) Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow-up of the first series of 25 patients. Heart 83:326-331
16. Faber L, Seggewiss H, Fassbender D, Bogunovic N, Strick S, Schmidt HK, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic cardiomyopathy: acute results in 66 patients with reference to myocardial contrast echocardiography. Z Kardiol 87:191-201
17. Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy: results with respects to intraprocedural myocardial contrast echocardiography. Circulation 98 (22):2415-2421
18. Fananapazir L, E Cannon RO, Tripodi D, Panza JA (1992) Impact of dual chamber pacing in patients with hypertrophic obstructive cardiomyopthy with symptoms refractory to verapamil and β-adrenergic blocker therapy. Circulation 85:2149-2161
19. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D (1994) Long term results of dual chamber (DDD) pacing in obstructive cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 90:2731-2742
20. Gadler F, Linde C, Daubert C, McKenna W, Meisel E, Aliot E, Chojnowska L, Guize L, Gras D, Jeanrenaud X, Kappenberger L (1999) Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1-year of follow-up. PIC study group. Pacing in Cardiomyopathy. Eur Heart J 20(14):1044-1050
21. Gietzen FH, Leuner C, Obergassel L, Strunk-Müller C, Kuhn H (2002) Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy. New York Heart Association functional class III or IV, and outflow obstruction under provocable condition. Circulation 106:454-459
22. Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Müller C, Kuhn H (1999) Acute and long term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20:1342-1354
23. Jeanrenaud X, Goy JJ, Kappenberger L (1992) Effects of dual chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet 339:1318-1323
24. Kaltenbach M, Hopf R, Kober G, Bussmann WD, Keller M, Petersen Y (1979) Treatment of hypertrophic cardiomyopathy with verapamil. Br Heart J 42:35-42
25. Kappenberger L, Linde C, Daubert C, McKenna W, Meisel E, Sadoul N, Chojnowska L, Guize L, Gras X, Jeanrenaud X, Ryden L and the PIC Study Group (1997) Pacing in hypertrophic obstructive cardiomyopathy. Eur Heart J 18:1249-1256
26. Klues HG, Maron BJ, Dollar AL, Roberts WC (1992) Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy: Circulation 85:1651-1660
27. Klues HG, Roberts WC, Maron BJ (1991) Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Circulation 84:1188-1197
28. Knight C, Kurbaab AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Sigwart U (1997) Non surgical septal reduction for hypertrophic obstructive cardiomyopathy. Outcome in the first series of patients. Circulation 95:2075-2081
29. Kraijcer Z, Leachman RD, Cooley DA, Coronado R (1989) Septal myotomymyectomy versus mitral valve replacement in hypertrophic cardiomyopathy. Circulation 89:I-57-64
30. Kuhn H, Gietzen F, Leuner C, Gerenkamp T (1997) Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment. Eur Heart J 18:846-851
31. Kuhn H, Gietzen F, Leuner C, Schäfers M, Schober O. Strunk-Müller C, Obergassel L, Freick M, Gockel B, Lieder F, Raute-Kreinsen U (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic cardiomyopathy. Z Kardiol 89(Suppl 4):41-54
32. Lakkis N, Kleiman N, Killip D, Spencer W III (1997) Hypertrophic obstructive cardiomyopathy: alternative therapeutic options. Clin Cardiol 20:417-418
33. Lakkis N, Nagueh SF, Kleiman NS, Killip D, He ZX, Verani MS, Roberts R, Spencer WH 3rd (1998) Echocardiography - guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 98 (17):1750-1755
34. Maron BJ (2002) Hypertrophic cardiomyopathy. A systematic review. JAMA 287:1308-1320
35. Maron BJ (2000) Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet 355:425-426
36. Maron BJ, Bonow RO, Cannon RO, Leon BL, Epstein SE (1987) Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology and therapy. N Engl J Med 316:780-789 and 844-852
37. Maron BJ, Nishimura RA, Danielson GK (1998) Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation 98:2505-2508
38. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS (1990) Assessment of permanent dual-chamber pacing as a treatment for drug refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 99(22):2927-2933
39. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flyenring BP, Casey SA, Gohman TE, Bongioanni S, Spirito P (2002) Clinical profile of stroke In 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 39(2):301-307
40. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NAM, Spirito P (2000) Efficiacy of implantable cardioverter defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342:365-373
41. Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R, Spencer WH 3rd (2001) Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 103:1492-1496
42. McKenna WJ, Behr ER (2002) Hypertrophic cardiomyopathy: Management, risk stratification and prevention of sudden death. Heart 87:169-176
43. McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M (1997) Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 77:130-132
44. McIntosh CL, Maron BJ (1988) Current operative treatment of obstructive hypertrophic cardiomyopathy. Circulation 78:487-495
45. McIntosh CL, Maron BJ, Cannon RO, Klues HG (1992) Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Circulation 86(Suppl II):II-60-67
46. Meisel E, Ranwolf T, Burghardt M, Kappenberger L (2000) Pacemaker therapy of hypertrophic obstructive cardiomyopathy. PIC (Pacing in Cardiomyopathy) Study Group. Herz 25:461-466
47. Messmer BJ (1994) Extended myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg 58:575-577
48. Morrow AG, Brockenbrough EC (1961) Surgical treatment of IHSS: Technique and hemodynamic results of ventriculomyotomy. Ann Surg 154:181-189
49. Morrow AG, Reitz BA, Epstein SE, Concle DM, Itscoitz SB, Redwood DR (1975) Operative treatment in hypertrophic subaortic stenosis. Techniques and the results of pre- and post-operative assessment in 83 patients. Circulation 52:88-102
50. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik AJ, Spencer WH (2001) Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic cardiomyopathy. J Am Coll Cardiol 38:1701-1706
51. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, Allison TG, Tajik AL (1997) Dual chamber pacing for hypertrophic cardiomyopathy: A randomized, double-blind, crossover trial. J Am Coll Cardiol 29:435-441
52. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ (2001) Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104:2517-2524
53. Pollick C (1982) Muscular subaortic stenosis. Hemodynamic and clinical improvement after disopyramide. N Engl J Med 307:997-999
54. Qin JX, Shiota T, Lever HM (2001) Outcome of patients with hypertrophic cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 38:1994-2000
55. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P (1996) Report on the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 93:841-842
56. Roberts R, Sigwart U (2001) New concepts in hypertrophic cardiomyopathy, part I and II. Circulation 104:2213-2216 and 2249-2252
57. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki J, McKenna WJ (1990) Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 15:1279-1285
58. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ (1997) Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 96:2987-2991
59. Schöndube FA, Klues HG, Reith S, Flachskampf FA, Messmer BJ, Hanrath P (1995) Long term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 92(Suppl II):II-122-127
60. Seggewiss H (2000) Percutaneous transluminal septal myocardial ablation: a new treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 21:704-707
61. Seggewiss H, Faber L, Gleichman U (1999) Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 47:94-100
62. Seggewisss H, Gleichmann U, Faber L, Faßbender D, Schmidt HK, Strick S (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cadiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 31(2):252-258
63. Seiler C, Hess OM, Schoenbeck M, Turine J, Jenni R, Turine M, Krayenbuehl HP (1991) Long term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study. J Am Coll Cardiol 17:634-642
64. Shah PM, Taylor RD, Wong M (1984) Abnormal mitral valve coaptation in hypertrophic obstructive cardiomyopathy: Proposed role in systolic anterior motion of mitral valve. Am J Cardiol 54:1039-1046
65. Shirani J, Maron BJ, Cannon RO III, Shahim S, Roberts WC (1993) Clinicopathological features of hypertrophic cardiomyopathy managed by cardiac transplantation. Am J Cardiol 72:434-440
66. Sigwart U (1995) Non-surgical reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211-214
67. Spencer WH, Roberts R (2000) Alcohol septal ablation in hypertrophic obstructive cardiomyopathy. The need for a registry. Circulation 102:600
68. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ (2000) Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342:1778-1785
69. Spirito P, Maron BJ, Bonow RO, Epstein SE (1987) Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 60:123-129
70. Spirito P, Seidman CE, McKenna WJ, Maron BJ (1997) The management of hypertrophic cardiomyopathy. N Engl J of Med 11:775-785
71. Teare D (1958) Asymmetrical hypertrophy of the heart in young adults. Br Heart J 20:1-8
72. Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ (2001) Hypertrophic cardiomyopathy: histopathological features of sudden death In cardiac troponin T disease. Circulation 104:1380-1384
73. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, Spirito P, Matsumori A, Moravec CS, Seidman JG et al (1995) Mutations in the genes for cardiac Troponin T and alpha-Tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 332:1058-1064
74. Watkins H (2000) Sudden death in hypertrophic cardiomyopathy. N Engl J Med 372:422-424
75. Wigle ED, Rakowski H, Kimball BP, Williams WG (1995) Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 92:1680-1692